Animal Cancer Foundation
Animal Cancer Foundation is a 501(c) 3 organization dedicated to finding a cure for cancer by funding research in and increasing public awareness of comparative oncology, the study of naturally occurring cancers in people and pets to discover new treatments for both.
Association of Pediatric Hematology/Oncology Nurses
APHON’s mission is to support and advance nurses and their practice in order to optimize outcomes for children, adolescents, and young adults with cancer and blood disorders and their families.
To discover, develop and deliver innovative medicines that help patients prevail over serious diseases.
Elephants and Tea
Elephants & Tea, is a magazine for adolescent and young adult (AYA) cancer patients and survivors written by AYA cancer patients and survivors telling their story in their own words.
Through stories & artwork our goal is to help AYA patients and survivors experience relief through self-expression, inspire others during their cancer journey and connect with supportive organizations across the nation.
Cancer is the Elephant in the room. Tea is the relief conversation provides.
What is your elephant?
Be Heard. Join the Herd.
GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Identify novel drug applications for rare diseases. We work with patient groups and charities to help identify drug repurposing opportunities and help translate basic research into tangible potential treatments.
KBI is a leading biopharmaceutical contract services company providing fully integrated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. To date, the company has served more than 300 clients around the world, including most of the top 10 pharmaceutical companies.
Leukemia & Lymphoma Society
Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.
Loxo Oncology is dedicated to developing highly selective medicines for patients with genetically defined cancers. We base our approach on two scientific trends: the increasing use of genetic testing in cancer clinical medicine and improving chemistry approaches to building highly selective inhibitors against single targets in the cancer cell. Some people develop cancers that are caused by a single inappropriate DNA change, known as “oncogenic drivers.” When a genetic test identifies a patient with an oncogenic driver, there should be a personalized medicine to address this error in the DNA that is leading to the cancer. Loxo Oncology is developing a pipeline of highly selective drugs that inhibit oncogenic drivers in cancer.
Making Cancer Fun
Making Cancer Fun is the go-to resource for families facing childhood cancer. It offers practical ideas, tools and tips for parents interwoven with a personal story of resiliency and hope. Additionally, each chapter contains interactive workbook pages for parents, designed to meet the individual needs of their child. Get ready for a new cancer conversation!
National Brain Tumor Society
National Brain Tumor Society (NBTS) unrelentingly invests in, mobilizes and unites our community to discover a cure, deliver effective treatments, and advocate for patients and care partners.
Notable’s mission is to change the way cancer is treated, which starts with putting patients first. We’ve developed a personalized treatment service for cancer patients that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor. Focusing on individual patients and existing treatments, we’re discovering novel uses of drugs and defining mechanisms underlying development of cancer progression and drug resistance. Using modern data science and robotics, Notable is building a scalable, iterative model with the ultimate aim of turning treatment selection into a data problem.
Discover new ways to improve and extend people’s lives
Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.
The company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.
There are many benefits to joining CAC2. The primary benefit to you is the opportunity to establish stronger relationships and increased trust for coordinated action and collaboration with other groups and individuals who advocate for children with cancer.
We help childhood cancer advocates and organizations incubate and hatch golden egg ideas for our members to share. If you think you have an idea worth rolling out into the community, we want to help you.